Acute myeloid leukemia (AML) is a heterogeneous, highly malignant neoplasm. Apoptosis is a complex process executed by caspases and suppressed by the inhibitor of apoptosis (IAP) family. Neuronal apoptosis inhibitory protein (NAIP), IAP's member, may play an exceptional role in the mechanisms of tumors' resistance to chemotherapy. The aims of the study were to assess the expression of NAIP in leukemic blasts of AML patients using flow cytometry and to evaluate its influence on disease outcome. NAIP expression was found in 106 out of 108 patients. A higher complete response rate was associated with a low expression of NAIP, age < 60 yo, and white blood cell count < 20 G/L (p = 0.009, p = 0.033, and p = 0.076, respectively) in univariate analyses and a low NAIP expression and age < 60 yo (p = 0.025 and p = 0.013, respectively) in multivariate analyses. Longer overall survival (OS) in the univariate analysis was influenced by a low NAIP expression, age < 60 yo, and intensive chemotherapy (p = 0.033, p < 0.001, and p < 0.001, respectively). In the intensively treated group, better OS was observed in patients with age < 60 yo, de novo AML, and a low NAIP expression (p = 0.03, p = 0.024, and p = 0.07, respectively). In multivariate analysis, longer OS was associated with age < 60 yo (p = 0.009) and de novo AML (p = 0.007). In conclusion, we suggest that NAIP might play an adverse role in response to chemotherapy.
Introduction
Acute myeloid leukemia (AML) is an infrequent (1.3%), highly malignant neoplasm responsible for a large number of cancer-related deaths [1, 2] . In the USA and other highly developed countries, the incidence has been near stable over the last years and is about 4 cases per 100,000 citizens per year [1, 2, 3] . The median age at diagnosis is 67 years [1] [2] [3] . AML is a heterogeneous and complex disease in which genomic and proteomic alterations and the interactions between them result in various apoptosis abnormalities [1] [2] [3] .
Apoptosis, programmed cell death, is a highly regulated cellular signaling pathway important for normal development that is needed for the correct functioning of diverse processes such as embryogenesis and tissue homeostasis, as well as tumorigenesis in multicellular organisms [4] . The apoptotic signaling cascades can be initiated by various extracellular (extrinsic pathway) or intracellular (intrinsic pathway) stimuli. Apoptosis is executed by a family of cysteine proteases known as caspases, which are produced in cells as inactive zymogens and become active proteases subsequent to proteolysis [5] [6] [7] [8] . Once active, caspases cleave a limited number of substrates that result in the destruction of the cells and their eventual disposal by phagocytic cells.
The inhibitors of apoptosis (IAP) are a family of proteins comprising intrinsic negative regulators of the caspase cascade; these are the only known endogenous proteins that interfere with the activity of both initiator (caspases 8 and 9) and effector enzymes (caspases 3, 6, and 7) [9] [10] [11] . Eight human IAP family members have been recognized: neuronal apoptosis inhibitory protein (NAIP), X-linked inhibitors of apoptosis protein (XIAP), cellular inhibitors of apoptosis protein 1 (cIAP1), cellular inhibitors of apoptosis protein 2 (cIAP2), survivin, baculoviral IAP repeat-containing ubiquitin-conjugating enzyme (BRUCE/apollon), livin (ML-IAP, KIAP) and IAP-like protein 2 (ILP-2) [10] . Various IAP family members have been shown to influence the outcome of AML, either alone or in combination [12] [13] [14] [15] . It has been demonstrated that overexpression of IAP family members in AML leukemic cells correlates with a low complete remission (CR) rate and shorter overall survival (OS) [16] [17] [18] . Especially, a high survivin protein expression is associated with shorter OS [16] . Studies on XIAP have shown that its overexpression was associated with a lower CR rate and worse OS as compared to the in patients with absent or low XIAP expression [17, 18] . Various levels of IAP family member expression have been described in AML patients. Simultaneously, a high expression of 1, 2, 3, and 4 proteins has been found to be strongly correlated with CR rates 71%, 60%, 57%, and 33%, respectively [16] .
Additionally, absent or a low expression of all examined proteins (XIAP, cIAP1, cIAP2, and survivin) was associated with 100% CR rate [16] .
These results demonstrate that apoptosis resistance is very complex in AML patients.
NAIP is comprised of three 3 zinc-binding baculovirus IAP repeat (BIR) domains and, uniquely among IAPs, a nucleotide-binding and oligomerization (NOD) domain and a leucine-rich repeat (LRR) domain [10, 19] . NAIP has emerged as an important regulator of innate immune signaling [20] . Overexpression of this protein has been described in inflammatory disorders such as neurodegenerative disorder spinal muscular atrophy (SMA) [21] . NAIP is also responsible for the intracellular recognition of flagellin, the main structural component of the bacterial flagellum. It takes part in the formation of the inflammasome, multiprotein oligomer responsible for the activation of inflammatory responses. This process activates procaspese-1 cleavage and the extracellular secretion of proinflammatory interleukins: IL-1 and IL-18 [22] . NAIP also has the same antiapoptotic function as other IAPs.
Apoptosis inhibition takes place via blockade of caspases 3, 7, and 9 [20, 21] . All these processes suggest that NAIP possesses unique activity, which might be due to highly variable region of the chromosome (5q13) that encodes NAIP. The overexpression of NAIP has been described in inflammatory diseases, motor neurons in SMA, multiple sclerosis, Alzheimer's and Parkinson's diseases. Moreover, the presence of NAIP has been noted in some malignancies, including hematological ones: lymphomas, myelodysplastic syndromes (MDS), and AML cells [23] [24] [25] [26] . The highest expression was noticed in AML refractory to chemotherapy [25] .
Studies on NAIP expression suggest that it may play an exceptional role in neoplasms, including leukemia; however, little information exists about its exact role in AML.
Hence, the present study examines the expression of NAIP protein and its influence on treatment outcome and survival of AML patients.
Materials and methods

Patients
The study involved 108 patients with newly diagnosed AML who Myeloid Leukemia [3, 24] . Briefly, complete response (CR) was defined as the presence of less than 5% of bone marrow (BM) blasts with a neutrophil count higher than 1.0 G/L, a platelet count higher than 100 G/L, and no extramedullary disease. Partial remission (PR) was established with either 5-25% BM blasts, a 50% or a higher decrease in BM blasts, or BM blasts < 5% but with the presence of Auer rods. No response (NR) was established for the patients who did not fulfill any of the abovementioned criteria. Early death (ED) was defined as a death from any cause within 4 weeks after the induction therapy and was considered as treatment failure. Diseasefree survival (DFS) was calculated from the first day of CR until documentation of a relapse [3] . OS was calculated from the time of diagnosis until death [3] .
Laboratory tests
Blood and BM sampling
Venous blood or BM samples were collected at the time of diagnosis into pyrogen-free ethylenediaminetetraacetic acid (EDTA) tubes.
Immunophenotyping of leukemic cells was performed routinely in the whole peripheral blood or BM using flow cytometry: the "lysed- System, Minneapolis, MN, USA) was performed at 4°C overnight.
On the following day, the samples were washed in PBS, centrifuged (5 minutes, 1100 rpm), and incubated for 120 minutes with secondary FITC-conjugated Abs at a dilution of 1:20. Afterwards, the samples were washed in PBS, centrifuged (5 minutes, 1100 rpm) before being resuspended in 400 µL PBS, and subjected to the flow cytometry analysis. At the same time, samples with isotype controls were also prepared (normal rabbit IgG control, 1:100 dilution; R&D System, Minneapolis, MN, USA). All preparations have been previously described in detail [16, 30] . 
Flow cytometry analysis
Statistical analysis
The statistical analysis was performed with Statistica 12.0 (Tulusa, OK, USA) software. Correlations between the variables were assessed using the Spearman rank test. OS was estimated using the Kaplan-Meier method. The chi-square and logistic regression tests were applied to investigate the dependence between individual factors and CR rate. The log-rank test was used to evaluate the univariate effects of particular variables on OS. For the multivariate analysis of factors affecting OS, the Cox proportional hazard regression model was applied. Comparisons and correlations between the examined parameters were considered as significant when p was < 0.05.
Results
Intracellular flow cytometry protein expression
NAIP protein expression was found in 106 of 108 (98%) newly diagnosed AML patients. Median expression was 11.9% (range 1-79.6%).
NAIP expression and treatment outcome
Response to the treatment Thirty-three (67%) of 49 intensively treated patients achieved CR.
The univariate analysis found age below 60 yo, white blood cell (WBC) count < 20 G/L and a low expression of NAIP protein to be associated with a higher probability of CR achievement (p = 0.033, p = 0.076, and p = 0.009, respectively, Table II ).
The multivariate analysis found age below 60 yo and low NAIP protein expression to be the only factors associated with a higher probability of CR achievement (p = 0.013, and p = 0.025, respectively, Table III) .
Overall survival
Median time of OS for the whole cohort of patients was 4.7 months (range 0.03-120.6 months). The probability of 5-year survival in our cohort was 15.5%. In the univariate log-rank analysis, better OS was influenced by age less than 60 yo, intensive therapy and a low expression of NAIP protein (p < 0.001, p < 0.001, and p = 0.033, respectively, Table IV ). In multivariate analysis, intensive treatment was the only significant factor associated with longer OS (p <
Fig. 1. Expression of NAIP in flow cytometry
0.001, Table V ). The analysis of the intensively treated group alone showed that better OS was influenced by age < 60 yo and de novo AML (p = 0.03 and p = 0.024, respectively, Table IV ) and longer survival tended to be observed in patients with a low expression of NAIP (p = 0.07, Table IV ). Additionally, in multivariate analysis, age below 60 yo and de novo AML were important for longer OS (p = 0.009 and p = 0.007, respectively, Table V) .
Disease-free survival
Median time of DFS for the whole cohort of patients was 15.5 months (range 1.8-119 months). The probability of a 5-year DFS in the intensively treated cohort was 55%. Age < 60 yo was the only factor that influenced longer DFS (p = 0.016).
Relationship between the expression of NAIP protein and standard AML risk factors
Expression of NAIP protein in leukemic blasts did not differ significantly in the risk groups divided according to age (< 60 yo vs. 
CR -complete remission; WBC -white blood cell; NAIP -neuronal apoptosis inhibitor protein
The present study is the first to assess the expression of NAIP protein in AML cells using cytometry. It identified NAIP expression in 98% of AML patients with a range 1-79.6%. The presence of NAIP mRNA and protein expression in leukemic cells suggests that it may be an important factor for escape from cell death.
Although various IAP family members have been shown to have an impact on CR achievement and survival in AML patients [15, 16] , no data have been presented regarding the influence of NAIP protein on treatment outcome and survival; however, the univariate and multivariate analyses in the present study indicate that a low expression of NAIP was associated with a higher CR rate in AML (85% vs. 47%; p = 0.009 and p = 0.025, respectively). Moreover, a low NAIP protein expression was associated with longer survival in the whole group and a trend was observed toward better OS in intensively treated patients (p = 0.033 and p = 0.07, respectively).
The influence of NAIP expression on AML outcome suggests that it modulates leukemic cell survival.
Choi et al. measured mRNA NAIP expression in 117 breast cancers and 10 normal breast tissues using RT-PCR [31] . NAIP was present in all breast samples. It was overexpressed in the cancer tissue as compared to healthy breast tissue, and particularly a high expression was observed in patients with unfavorable risk factors [31] . The authors did not find any correlation between NAIP expression and 3-year relapse-free survival. However, it should be mentioned that this is quite a short period of time in breast cancer patients, and the authors underline that longer observation in larger patients' group is necessary to determine the role of NAIP in breast cancer.
Nevertheless, these findings regarding the significant role of NAIP Chiu et al. showed using RT-PCR and Western blot approaches that NAIP mRNA and protein were expressed in prostatic cancer cells [32] . Moreover, the authors observed that increased NAIP expression significantly lowered the response to androgen therapy in an in vitro
and in vivo mouse model [32] . It also corresponded with increased DNA-binding activity of NF-kappaB, an NAIP up-regulator, and resulted in treatment resistance [32] . In addition, a Spanish group studied NAIP expression in 95 patient samples of prostatic cancer and 35 cases of benign prostatic hyperplasia as well as 10 normal prostatic cells using immunohistochemistry. NAIP protein was present only in samples with prostatic neoplasm, and this protein expression was in more than 60% of cells [33] . Normal prostatic cells displayed a lack of NAIP protein expression; unfortunately, NAIP expression was not correlated with clinical and pathological parameters [34] .
Nevertheless, studies on prostate cancer suggest the NAIP may play a role in carcinogenesis.
Additionally, the expression of IAP family members (XIAP, cIAP1, and NAIP) was found to increase with carcinoma stage in a hamster model of squamous-cell carcinogenesis. Simultaneous RT-PCR assessment of p53 mutation and IAP methylation suggests that IAP expression might be modulated by both genetic (mutant p53) and epigenetic mechanisms [35] . This observation suggests that combined treatment may be a future therapeutic option.
Our results are convergent with those in breast and prostatic cancer. Higher expression of NAIP is an adverse prognostic factor in treatment outcome and survival of AML patients.
Currently, based on the knowledge about IAP's family, 2 types of mechanisms are under investigation in phase I and II of clinical trials in the cancer patients. One is based on proapoptotic Smac small molecule, which binds IAP's members and promotes activation of caspases leading to apoptosis [35] . The second mechanism uses pan-IAP inhibitor. The blockade of IAP's members induces cleavage of caspases 3 and 8 and activates apoptosis [36] . We may expect the development of the targeting treatment focusing on IAP's pathway in near future.
Conclusions
NAIP may play an important role in the response to chemotherapy and development of refractory disease. However, further studies are necessary to establish its exact role in the treatment of AML patients.
